Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors as of Sept. 30, 2022

Portfolio Holdings for Atlas Venture Life Science Advisors

Atlas Venture Life Science Advisors holds 17 positions in its portfolio as reported in the September 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Third Harmonic Bio Common Stock (THRD) 22.8 $207M 11M 18.97
Day One Biopharmaceuticals Common Stock (DAWN) 18.1 $164M 8.2M 20.03
Kymera Therapeutics Common Stock (KYMR) 16.5 $150M 6.9M 21.77
Dyne Therapeutics Common Stock (DYN) 12.5 $114M 8.9M 12.70
Replimune Group Common Stock (REPL) 5.9 $54M 3.1M 17.27
Vigil Neuroscience Common Stock (VIGL) 5.9 $53M 5.8M 9.10
Generation Bio Common Stock (GBIO) 4.9 $44M 8.3M 5.31
Aerovate Therapeutics Common Stock (AVTE) 4.3 $39M 2.3M 16.58
Akero Therapeutics Common Stock (AKRO) 3.7 $34M 994k 34.05
Ikena Oncology Common Stock (IKNA) 2.0 $18M 5.0M 3.55
Gemini Therapeutics Common Stock 1.0 $8.6M 5.3M 1.64
Xilio Therapeutics Common Stock (XLO) 0.9 $8.0M 2.8M 2.91
Magenta Therapeutics Common Stock 0.5 $4.9M 3.5M 1.41
F-star Therapeutics Common Stock 0.3 $3.1M 600k 5.12
AvroBio Common Stock (AVRO) 0.3 $2.9M 4.5M 0.64
Spero Therapeutics Common Stock (SPRO) 0.2 $2.1M 1.0M 2.00
Viridian Therapeutics Common Stock (VRDN) 0.2 $1.8M 90k 20.51